We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TREMFYA Janssen-Cilag Pty Ltd
Product name
TREMFYA
Sponsor
Accepted date
Jan-2025
Active ingredients
guselkumab
Proposed indication
TREMFYA is used to treat children aged 6 years and older with moderate to severe plaque psoriasis who are eligible for systemic (whole-body) therapy or phototherapy (ultraviolet light therapy).
Application type
C (new indication)
Publication date
Jan-2025